Severe PTEN deficiency is linked to resistance to treatment, particularly to targeted therapies involving the receptor tyrosine kinases (RTKs) pathway like trastuzumab, and advanced tumor stage.11 Targeting the PI3K/ AKT/ PTEN/ mTOR pathway increases patient survival by restoring drug sensitivity in cancer stem cells (CSCs). The gene discussed is AKT1; the disease is cancer.